Launch — Access limited to 250 Members to ensure personalized follow-up quality.
Mechanism of ActionKey BenefitsDosage & FormsIn the Singular FormulaSafety & PrecautionsScientific StudiesFrequently Asked Questions
Glucosamine

Glucosamine

Glucosamine · GlcN · Glucosamine sulphate · 2-amino-2-deoxy-D-glucose

GlycansTissue structure

Glucosamine sulfate is an amino sugar the body makes on its own to maintain cartilage. The best-established effect concerns knee comfort in adults whose cartilage has worn down: a synthesis of seventeen controlled trials measures a small to moderate reduction in discomfort, which holds up when manufacturer-funded trials are set aside. Stiffness moves the same way across sixty-one compared trials. In athletes, after an acute knee injury, one trial reports a gain in range of motion at four weeks. A more preliminary signal, drawn from a very large cohort, links regular use to better longevity, with no cause-and-effect link established. Preserving mobility matters for what follows: when movement becomes rare, physical activity drops and muscle capital erodes. That joint comfort, one of the concrete footholds of healthspan, is what the trials summarised above measure.

Last updated: August 11, 2026

Mechanism of Action

Glucosamine is built into glycosaminoglycan chains, long brush-shaped molecules that line joint surfaces. These chains draw in water and form a viscous gel that cushions mechanical stress. The sulfate group supplies the sulfur needed to sulfate those chains, a process that governs their three-dimensional architecture and their water-holding capacity.

Glucosamine also takes part in the synthesis of hyaluronic acid within synovial fluid, the natural lubricant of joints.

Oral intake does reach that compartment. After fourteen days of daily intake, glucosamine was measured in the synovial fluid of twelve people, at concentrations correlated with those found in their blood at the same moment. This is the only route by which an external intake can reach the cartilage matrix.

Key Benefits

  • Moderate

    Less bother from the knee day to day: a synthesis of seventeen controlled trials measures a reduction in knee discomfort in adults whose cartilage has worn down, at 1,500 mg per day of glucosamine sulfate. The gap holds when only trials run outside industry funding are kept.

  • Moderate

    A less stiff joint: a comparison of sixty-one controlled trials places glucosamine among the oral intakes that improve knee and hip stiffness, at the same daily dose of 1,500 mg.

  • Moderate

    Regaining range after a knee injury: in one hundred and six competitive athletes, a randomized placebo-controlled trial measures a gain in flexion and extension after twenty-eight days of intake, with no effect on pain or swelling.

  • Emerging

    A benefit that may reach beyond the joint: an observational study from the UK Biobank cohort, covering more than 466,000 people, links regular glucosamine use to lower cardiovascular risk and lower all-cause mortality. This signal remains preliminary, with no established cause-and-effect link.

Dosage & Forms

Three oral forms exist on the market: glucosamine sulfate, glucosamine hydrochloride and N-acetyl-glucosamine. Trials that measured a joint effect almost all used the sulfate form, at 1,500 mg per day in a single intake, which corresponds to 1,178 mg of glucosamine.

The gap between the two salts has been quantified. An analysis of fifteen trials places the effect at 0.44 on a standardized scale for the sulfate, against 0.06 for the hydrochloride. Its authors immediately note that a gap of the same size separates one manufacturer's trials from the rest of the literature, which rules out attributing the difference to salt chemistry alone.

Two studies do close the question of the carrier salt. A direct double-blind comparison in ninety people does not separate sulfate with potassium chloride from sulfate with sodium chloride. A kinetics study in healthy volunteers likewise finds no difference in absorption between a patented brand and a generic one.

Absorption stays proportional to dose between 750 and 1,500 mg. In France, the amount supplied by one daily intake must stay below the pharmacological threshold of 1,119 mg of glucosamine.

In the Singular Formula

Inclusion rationale

Amino sugar naturally present in human cartilage, where it is a key constituent of glycosaminoglycans and proteoglycans, the molecules that give cartilage its cushioning and mechanical resistance properties. Glucosamine is the direct precursor of hyaluronic acid and keratan sulfates, essential components of the extracellular matrix of articular cartilage. Its endogenous production by chondrocytes (cartilage cells) decreases with age, contributing to the progressive thinning of cartilage observed during aging. The sulfate form is preferred because the sulfate group is itself necessary for the synthesis of sulfated glycosaminoglycans. Numerous clinical studies have evaluated glucosamine sulfate at doses of 1,500 mg/day, making it one of the most documented joint supplements in the world. Randomized trials spanning 3 years have shown a slowing of articular cartilage thickness loss measured by radiography. In the formula, glucosamine works in complementarity with undenatured type II collagen (also present). These two actives take distinct pathways: glucosamine provides the building blocks for glycosaminoglycans, while type II collagen modulates the immune response toward cartilage through oral tolerance. Two complementary mechanisms to support joint comfort.

Selected form

Patented active

Amino sugar naturally present in cartilage. The selected product is derived from the chitin of crustacean shells: it is not suitable for vegetarian or vegan diets. Quality: no excipient.

Formula dosage

0 to 1,118 mg.

Dose expressed as active substance, excluding excipients and carriers of the raw material.

Synergies in the formula

In the Singular formula, glucosamine sulfate works alongside several complementary bioactives. Type II collagen takes a distinct route, immune oral tolerance, and offers a second lever on joint comfort. Vitamin C acts as a cofactor in collagen synthesis: it supports the hydroxylation of proline and lysine, two amino acids that structure the collagen network. It contributes to normal collagen formation for the normal function of cartilage. Glycine and L-lysine supply two of the amino acids that this network consumes continuously. The oral hyaluronic acid in the formula is documented separately for skin hydration and barrier function. The data reviewed do not show that it reaches synovial fluid after ingestion, nor that it acts in joint synergy with glucosamine.

Linked Biomarkers

Combined eGFRHOMA-IRFasting Blood GlucoseCreatinineFasting InsulinCystatin C

Safety & Precautions

Glucosamine sulfate has more than thirty years of use behind it. Adverse effects reported in trials are limited to mild digestive upset, as frequent under placebo.

It is not recommended for people with diabetes or prediabetes, asthma, or those on vitamin K antagonist therapy, nor for pregnant or breastfeeding women. These reservations follow the opinion issued by the French food safety agency in 2019. In thirty-eight adults with no known blood sugar abnormality, six weeks at 1,500 mg per day raised an index of insulin resistance. A review of eleven studies concludes that the data remain divided, the effect showing mainly in people already least sensitive to insulin.

A three-month trial measured a rise in internal eye pressure, more marked after sixty. A second trial, over six months, found nothing. Ongoing ophthalmic follow-up is worth mentioning.

Glucosamine salts supply potassium or sodium: their use calls for caution where sodium, potassium or calcium intake is controlled. Where impaired kidney function is declared, the Singular formula sets glucosamine aside.

The selected form comes from the chitin of crustacean shells. The crustacean allergen is among its declared components.

Scientific Studies

AuthorsYearTypeJournal

Effects of Oral Glucosamine Sulfate on Osteoarthritis-Related Pain and Joint-Space Changes: Systematic Review and Meta-Analysis

Meta-analysis restricted to glucosamine sulfate. On pain, seventeen trials give an effect of 0.35, falling to 0.19 when only trials without industry involvement are kept, but still measurable. On joint space narrowing, four trials give 0.10, a gap that is not significant.

Glucosamine for pain in osteoarthritis: why do trial results differ?

Analysis of why fifteen trials diverge. The effect reaches 0.44 for the sulfate against 0.06 for the hydrochloride, but also 0.55 for one manufacturer's trials against 0.11 for the rest: form and sponsor vary together.

Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank

Individual patient data meta-analysis of five industry-independent trials, 1,625 people. No difference from placebo on pain or function, at three months or twenty-four months, and in no subgroup.

Comparative effectiveness of glucosamine, chondroitin, acetaminophen or celecoxib for the treatment of knee and/or hip osteoarthritis: a network meta-analysis

Indirect comparison of sixty-one randomized trials. On stiffness, glucosamine reaches an effect of 0.36, of the same order as the pharmacological comparator used.

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

The largest trial ever run, 1,583 people over twenty-four weeks, using glucosamine hydrochloride. No pain reduction across the whole group; a signal appears only in the most affected subgroup, combined with chondroitin.

Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial

Founding three-year trial, 212 people: the placebo group loses 0.31 mm of knee joint space, the treated group 0.06 mm. Two later meta-analyses, covering more numerous and more independent trials, do not reproduce this structural effect.

Comparable clinical outcomes between glucosamine sulfate-potassium chloride and glucosamine sulfate sodium chloride in patients with mild and moderate knee osteoarthritis: a randomized, double-blind study

The only direct comparison of the two carrier salts, ninety people over sixteen weeks. No difference between sulfate with potassium chloride and sulfate with sodium chloride, on functional scores or tolerance. The trial had no placebo arm.

Glucosamine administration in athletes: effects on recovery of acute knee injury

Randomized placebo-controlled trial in 106 competitive athletes after an acute knee injury. Flexion and extension significantly better at twenty-eight days; pain and swelling unchanged at every measurement point.

Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank

Prospective study of 466,039 participants followed for seven years, linking habitual glucosamine use to lower cardiovascular risk. The design is observational: it measures an association, not an effect.

Glucosamine and Cancer Incidence in Osteoarthritis: A Prevalent New-User Cohort Design

Study designed to neutralize the selection bias of cohorts of already-established users: 20,541 people starting glucosamine, matched to as many non-users, followed for eight years. No reduction in cancer incidence.

Frequently Asked Questions

Discover all our bioactives